Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation

World Journal of Gastroenterology

Volumn 24, Issue 1, 2018, Pages 5-14

  Shen, Zhao Hua ^a,b   Zhu, Chang Xin ^a,b   Quan, Yong Sheng ^a,b   Yang, Zhen Yu ^a,b   Wu, Shuai ^a,b   Luo, Wei Wei ^a,b   Tan, Bei ^a,b   Wang, Xiao Yan ^a,b  

^a Hunan Key Laboratory of Skin Caner and Psoriasis   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinical application; Fecal microbiota transplantation; Intestinal microbiota; Mechanism; Probiotics; Ulcerative colitis

Indexed keywords

MESALAZINE; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

BACTERIUM; BIFIDOBACTERIUM; DRUG MECHANISM; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SAFETY; T LYMPHOCYTE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ANIMAL; COLON; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; TREATMENT OUTCOME;

ANIMALS; BACTERIA; COLITIS, ULCERATIVE; COLON; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; PROBIOTICS; TREATMENT OUTCOME;

EID: 85040464155     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v24.i1.5     Document Type: Review

References (96)

1. Ahmed J, Reddy BS, M?lbak L, Leser TD, MacFie J. Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study. Int J Surg 2013; 11: 1131-1136 [PMID: 24060951 DOI: 10.1016/j.ijsu.2013.08.019]
2. Hansen J, Gulati A, Sartor RB. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol 2010; 26: 564-571 [PMID: 20871399 DOI: 10.1097/ MOG.0b013e32833f1195]
3. Oelschlaeger TA. Mechanisms of probiotic actions - A review. Int J Med Microbiol 2010; 300: 57-62 [PMID: 19783474 DOI: 10.1016/j.ijmm.2009.08.005]
4. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 2011; 10: 66-78 [PMID: 22101918 DOI: 10.1038/nrmicro2690]
5. Dicksved J, Schreiber O, Willing B, Petersson J, Rang S, Phillipson M, Holm L, Roos S. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 2012; 7: e46399 [PMID: 23029509 DOI: 10.1371/journal.pone.0046399]
6. Sartor RB. Mechanisms of disease: pathogenesis of Crohn? s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407 [PMID: 16819502 DOI: 10.1038/ ncpgasthep0528]
7. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-1049 [PMID: 21871249 DOI: 10.1016/j.cgh.2011.08.014]
8. Actis GC, Pellicano R. The pathologic galaxy modulating the genotype and phenotype of inflammatory bowel disease: comorbidity, contiguity, and genetic and epigenetic factors. Minerva Med 2016; 107: 401-412 [PMID: 27314869]
9. Alipour M, Zaidi D, Valcheva R, Jovel J, Mart?nez I, Sergi C, Walter J, Mason AL, Wong GK, Dieleman LA, Carroll MW, Huynh HQ, Wine E. Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. J Crohns Colitis 2016; 10: 462-471 [PMID: 26660940 DOI: 10.1093/ecco-jcc/jjv223]
10. Scaldaferri F, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Bo?koski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013; 2013: 435268 [PMID: 23991417 DOI: 10.1155/2013/435268]
11. Seksik P. [Gut microbiota and IBD]. Gastroenterol Clin Biol 2010; 34 Suppl 1: S44-S51 [PMID: 20889004 DOI: 10.1016/ S0399-8320(10)70020-8]
12. Sommer F, B?ckhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238 [PMID: 23435359 DOI: 10.1038/nrmicro2974]
13. Fukumoto S, Toshimitsu T, Matsuoka S, Maruyama A, Oh-Oka K, Takamura T, Nakamura Y, Ishimaru K, Fujii-Kuriyama Y, Ikegami S, Itou H, Nakao A. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol Cell Biol 2014; 92: 460-465 [PMID: 24518984 DOI: 10.1038/icb.2014.2]
14. Kaur N, Chen CC, Luther J, Kao JY. Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2011; 2: 211-216 [PMID: 21983063 DOI: 10.4161/gmic.2.4.17863]
15. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010; 1801: 1175-1183 [PMID: 20691280 DOI: 10.1016/j.bbalip.2010.07.007]
16. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 1997; 8: 523-532 [PMID: 9149903]
17. Rose DJ, DeMeo MT, Keshavarzian A, Hamaker BR. Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern. Nutr Rev 2007; 65: 51-62 [PMID: 17345958]
18. Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, Wang BM. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015; 21: 102-111 [PMID: 25574083 DOI: 10.3748/wjg.v21.i1.102]
19. Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol Sci 2015; 16: 7493-7519 [PMID: 25849657 DOI: 10.3390/ijms16047493]
20. Bamias G, Nyce MR, De La Rue SA, Cominelli F; American College of Physicians; American Physiological Society. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143: 895-904 [PMID: 16365470]
21. Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 2017; 23: 4548-4558 [PMID: 28740343 DOI: 10.3748/wjg.v23.i25.4548]
22. Shang Q, Sun W, Shan X, Jiang H, Cai C, Hao J, Li G, Yu G. Carrageenan-induced colitis is associated with decreased population of anti-inflammatory bacterium, Akkermansia muciniphila, in the gut microbiota of C57BL/6J mice. Toxicol Lett 2017; 279: 87-95 [PMID: 28778519 DOI: 10.1016/j.toxlet.2017.07.904]
23. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608 [PMID: 22907164 DOI: 10.1038/nrgastro.2012.152]
24. Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, L?ffler T, B?chler MW, Schmidt J. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn?s disease. Gut 2005; 54: 944-949 [PMID: 15951539 DOI: 10.1136/gut.2004.045526]
25. Sechi LA, Scanu AM, Molicotti P, Cannas S, Mura M, Dettori G, Fadda G, Zanetti S. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn?s disease in Sardinia. Am J Gastroenterol 2005; 100: 1529-1536 [PMID: 15984976 DOI: 10.1111/j.1572-0241.2005.41415.x]
26. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner PR, Rotter JI, Yang H. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn?s disease. Gastroenterology 2006; 130: 1078-1085 [PMID: 16618402 DOI: 10.1053/ j.gastro.2006.02.013]
27. Reddy SS, Brandt LJ. Clostridium difficile infection and inflammatory bowel disease. J Clin Gastroenterol 2013; 47: 666-671 [PMID: 23507767 DOI: 10.1097/MCG.0b013e31828b288a]
28. Deshpande A, Pasupuleti V, Pant C, Rolston DD, Sferra TJ. Diagnostic testing for Clostridium difficile infection in patients with inflammatory bowel disease. J Clin Gastroenterol 2013; 47: 737-738 [PMID: 23751851 DOI: 10.1097/MCG.0b013e318295d4ec]
29. Markowitz JE, Brown KA, Mamula P, Drott HR, Piccoli DA, Baldassano RN. Failure of single-toxin assays to detect clostridium difficile infection in pediatric inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2688-2690 [PMID: 11569696 DOI: 10.1111/j.1572-0241.2001.04125.x]
30. Laharie D, Asencio C, Asselineau J, Bulois P, Bourreille A, Moreau J, Bonjean P, Lamarque D, Pariente A, Soul? JC, Charachon A, Coffin B, Perez P, M?graud F, Zerbib F. Association between entero-hepatic Helicobacter species and Crohn?s disease: a prospective cross-sectional study. Aliment Pharmacol Ther 2009; 30: 283-293 [PMID: 19438427 DOI: 10.1111/j.1365-2036.2009.04034.x]
31. Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 469-476 [PMID: 22221289 DOI: 10.1111/j.1365-2036.2011.04969.x]
32. Thomson JM, Hansen R, Berry SH, Hope ME, Murray GI, Mukhopadhya I, McLean MH, Shen Z, Fox JG, El-Omar E, Hold GL. Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? PLoS One 2011; 6: e17184 [PMID: 21383845 DOI: 10.1371/journal.pone.0017184]
33. Gradel KO, Nielsen HL, Sch?nheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501 [PMID: 19361507 DOI: 10.1053/j.gastro.2009.04.001]
34. Saebo A, Vik E, Lange OJ, Matuszkiewicz L. Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection. Eur J Intern Med 2005; 16: 176-182 [PMID: 15967332 DOI: 10.1016/ j.ejim.2004.11.008]
35. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83 [PMID: 12477765]
36. Chamaillard M, Cesaro A, Lober PE, Hober D. Decoding norovirus infection in Crohn?s disease. Inflamm Bowel Dis 2014; 20: 767-770 [PMID: 24351661 DOI: 10.1097/01.MIB.0000440613.83703.4a]
37. Huijsdens XW, Linskens RK, Taspinar H, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. Listeria monocytogenes and inflammatory bowel disease: detection of Listeria species in intestinal mucosal biopsies by real-time PCR. Scand J Gastroenterol 2003; 38: 332-333 [PMID: 12737451]
38. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]
39. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63: 1275-1283 [PMID: 24021287 DOI: 10.1136/ gutjnl-2013-304833]
40. Varela E, Manichanh C, Gallart M, Torrej?n A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 151-161 [PMID: 23725320 DOI: 10.1111/apt.12365]
41. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleski KJ, Golenbock D, Tzianabos AO, Kasper DL. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 2006; 203: 2853-2863 [PMID: 17178920 DOI: 10.1084/jem.20062008]
42. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010; 107: 12204-12209 [PMID: 20566854 DOI: 10.1073/pnas.0909122107]
43. Gaboriau-Routhiau V, Rakotobe S, L?cuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, Eberl G, Snel J, Kelly D, Cerf-Bensussan N. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31: 677-689 [PMID: 19833089 DOI: 10.1016/j.immuni.2009.08.020]
44. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498 [PMID: 19836068 DOI: 10.1016/j.cell.2009.09.033]
45. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 2009; 179: 186-193 [PMID: 19029003 DOI: 10.1164/rccm.200806-951OC]
46. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500: 232-236 [PMID: 23842501 DOI: 10.1038/ nature12331]
47. Gomes-Santos AC, de Oliveira RP, Moreira TG, Castro-Junior AB, Horta BC, Lemos L, de Almeida LA, Rezende RM, Cara DC, Oliveira SC, Azevedo VA, Miyoshi A, Faria AM. Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. Front Immunol 2017; 8: 30 [PMID: 28194152 DOI: 10.3389/fimmu.2017.00030]
48. Ventura M, Turroni F, Lugli GA, van Sinderen D. Bifidobacteria and humans: our special friends, from ecological to genomics perspectives. J Sci Food Agric 2014; 94: 163-168 [PMID: 23963950 DOI: 10.1002/jsfa.6356]
49. Hughes KR, Harnisch LC, Alcon-Giner C, Mitra S, Wright CJ, Ketskemety J, van Sinderen D, Watson AJ, Hall LJ. Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner. Open Biol 2017 [PMID: 28123052 DOI: 10.1098/rsob.160155]
50. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn' s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20: 21-35 [PMID: 24280877 DOI: 10.1097/01.MIB.0000437495.30052.be]
51. Sarowska J, Choroszy-Kr?l I, Regulska-Ilow B, Frej-M?drzak M, Jama-Kmiecik A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Adv Clin Exp Med 2013; 22: 759-766 [PMID: 24285463]
52. Cain AM, Karpa KD. Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med 2011; 17: 72-79 [PMID: 21614946]
53. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 327-334 [PMID: 22150569 DOI: 10.1111/j.1365-2036.2011.04939.x]
54. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1012-1018 [PMID: 18240278 DOI: 10.1002/ibd.20377]
55. Kruis W, Fric P, Pokrotnieks J, Luk?s M, Fixa B, Kasc?k M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]
56. Siaw YH, Hart A. Commentary: is Faecalibacterium prausnitzii a potential treatment for maintaining remission in ulcerative colitis? Aliment Pharmacol Ther 2013; 38: 551 [PMID: 23937459 DOI: 10.1111/apt.12404]
57. Agathou CL, Beales IL. Factors associated with the use of probiotics in patients with inflammatory bowel disease. F1000Res 2013; 2: 69 [PMID: 24555045 DOI: 10.12688/f1000research.2-69.v1]
58. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-121 [PMID: 21453880 DOI: 10.1016/j.crohns.2010.11.004]
59. Di Bella S, Drapeau C, Garc?a-Almod?var E, Petrosillo N. Fecal microbiota transplantation: the state of the art. Infect Dis Rep 2013; 5: e13 [PMID: 24470963 DOI: 10.4081/idr.2013.e13]
60. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953 [PMID: 24018052 DOI: 10.1053/j.gastro.2013.08.058]
61. Terveer EM, van Beurden YH, Goorhuis A, Seegers JFML, Bauer MP, van Nood E, Dijkgraaf MGW, Mulder CJJ, Vandenbroucke-Grauls CMJE, Verspaget HW, Keller JJ, Kuijper EJ. How to: Establish and run a stool bank. Clin Microbiol Infect 2017; 23: 924-930 [PMID: 28529025 DOI: 10.1016/j.cmi.2017.05.015]
62. Kazerouni A, Burgess J, Burns LJ, Wein LM. Optimal screening and donor management in a public stool bank. Microbiome 2015; 3: 75 [PMID: 26675010 DOI: 10.1186/s40168-015-0140-3]
63. Yang YX, Chen X, Gan HT. Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system: why were TLR3?s roles not tested? Gastroenterology 2014; 146: 1428 [PMID: 24681177 DOI: 10.1053/j.gastro.2014.01.069]
64. Dutta SK, Girotra M, Garg S, Dutta A, von Rosenvinge EC, Maddox C, Song Y, Bartlett JG, Vinayek R, Fricke WF. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. Clin Gastroenterol Hepatol 2014; 12: 1572-1576 [PMID: 24440222 DOI: 10.1016/ j.cgh.2013.12.032]
65. Sun D, Li W, Li S, Cen Y, Xu Q, Li Y, Sun Y, Qi Y, Lin Y, Yang T, Xu P, Lu Q. Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2016; 95: e3765 [PMID: 27281075 DOI: 10.1097/MD.0000000000003765]
66. Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, Xu H, Xiang J, He Z, Zhang T, Nie Y, Wu K, Fan D, Ji G, Zhang F. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 2015; 13: 298 [PMID: 26363929 DOI: 10.1186/s12967-015-0646-2]
67. Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, Li J. Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2015; 2015: 517597 [PMID: 26146498 DOI: 10.1155/2015/517597]
68. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 1569-1581 [PMID: 25223604 DOI: 10.1016/j.crohns.2014.08.006]
69. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, L?wenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D?Haens GR, Ponsioen CY. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149: 110-118.e4 [PMID: 25836986 DOI: 10.1053/j.gastro.2015.03.045]
70. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6 [PMID: 25857665 DOI: 10.1053/j.gastro.2015.04.001]
71. Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? Expert Rev Gastroenterol Hepatol 2015; 9: 781-795 [PMID: 25665875 DOI: 10.1586/17474124.2015.1013031]
72. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620-1630 [PMID: 24060759 DOI: 10.1038/ajg.2013.257]
73. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol 2014; 7: 1-13 [PMID: 26183502 DOI: 10.1007/ s12328-013-0440-8]
74. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 2014; 20: 1562-1567 [PMID: 24918321 DOI: 10.1097/MIB.0000000000000084]
75. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597-601 [PMID: 23542823 DOI: 10.1097/MPG.0b013e318292fa0d]
76. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108: 1367 [PMID: 23912408 DOI: 10.1038/ajg.2013.164]
77. Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. Clin Infect Dis 2014; 59: 319 [PMID: 24759832 DOI: 10.1093/cid/ciu278]
78. Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, H?rter G. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int 2013; 110: 108-115 [PMID: 23468820 DOI: 10.3238/arztebl.2013.0108]
79. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1036-1038 [PMID: 23669309 DOI: 10.1016/j.cgh.2013.04.045]
80. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2015; 2: ofv004 [PMID: 26034755 DOI: 10.1093/ofid/ofv004]
81. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002 [PMID: 22002980 DOI: 10.1093/cid/cir632]
82. Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, Wagner MA, Bennett BJ, Li L, DiDonato JA, Lusis AJ, Hazen SL. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015; 290: 5647-5660 [PMID: 25550161 DOI: 10.1074/jbc.M114.618249]
83. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology 2015; 149: 223-237 [PMID: 25982290 DOI: 10.1053/j.gastro.2015.05.008]
84. Hohmann EL, Ananthakrishnan AN, Deshpande V. Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med 2014; 371: 668-675 [PMID: 25119613 DOI: 10.1056/ NEJMcpc1400842]
85. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn?s disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8: 252-253 [PMID: 24184170 DOI: 10.1016/ j.crohns.2013.10.002]
86. Kellermayer R, Nagy-Szakal D, Harris RA, Luna RA, Pitashny M, Schady D, Mir SA, Lopez ME, Gilger MA, Belmont J, Hollister EB, Versalovic J. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol 2015; 110: 604-606 [PMID: 25853207 DOI: 10.1038/ajg.2015.19]
87. Pamer EG. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunol 2014; 7: 210-214 [PMID: 24399149 DOI: 10.1038/mi.2013.117]
88. Khoruts A, Weingarden AR. Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. Immunol Lett 2014; 162: 77-81 [PMID: 25106113 DOI: 10.1016/j.imlet.2014.07.016]
89. Woting A, Blaut M. The Intestinal Microbiota in Metabolic Disease. Nutrients 2016; 8: 202 [PMID: 27058556 DOI: 10.3390/ nu8040202]
90. Konturek PC, Haziri D, Brzozowski T, Hess T, Heyman S, Kwiecien S, Konturek SJ, Koziel J. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol 2015; 66: 483-491 [PMID: 26348073]
91. Ianiro G, Bibb? S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) 2014; 93: e97 [PMID: 25340496 DOI: 10.1097/MD.0000000000000097]
92. Kump PK, Gr?chenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, H?genauer C. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-2165 [PMID: 23899544 DOI: 10.1097/ MIB.0b013e31829ea325]
93. Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2015; 60: 27-29 [PMID: 25162366 DOI: 10.1097/MPG.0000000000000544]
94. Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, Marquis SR, Miller SI, Zisman TL. Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis. PLoS One 2015; 10: e0133925 [PMID: 26288277 DOI: 10.1371/journal.pone.0133925]
95. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 387-394 [PMID: 26519463 DOI: 10.1093/ecco-jcc/jjv203]
96. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017; 389: 1218-1228 [PMID: 28214091 DOI: 10.1016/S0140-6736(17)30182-4]